Clinical trial
A Phase 1 Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Healthy Normal Subjects
NCT02331433 is registered in ClinicalTrials.gov with CoMentis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Healthy Normal Subjects
- Lead sponsor
- CoMentis
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2014
- Completion date
- December 31, 2015
- Enrollment
- 58 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.